440 related articles for article (PubMed ID: 33946916)
1. Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?
Szumilak M; Wiktorowska-Owczarek A; Stanczak A
Molecules; 2021 Apr; 26(9):. PubMed ID: 33946916
[TBL] [Abstract][Full Text] [Related]
2. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
3. Hybrid Compounds as Multitarget Directed Anticancer Agents.
Kucuksayan E; Ozben T
Curr Top Med Chem; 2017; 17(8):907-918. PubMed ID: 27697050
[TBL] [Abstract][Full Text] [Related]
4. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
5. Recent advances (2015-2016) in anticancer hybrids.
Kerru N; Singh P; Koorbanally N; Raj R; Kumar V
Eur J Med Chem; 2017 Dec; 142():179-212. PubMed ID: 28760313
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Multidrug-Resistant Leukemia Cells by Novel Artemisinin-, Egonol-, and Thymoquinone-Derived Hybrid Compounds.
Gruber L; Abdelfatah S; Fröhlich T; Reiter C; Klein V; Tsogoeva SB; Efferth T
Molecules; 2018 Apr; 23(4):. PubMed ID: 29642419
[TBL] [Abstract][Full Text] [Related]
7. Current scenario of indole derivatives with potential anti-drug-resistant cancer activity.
Jia Y; Wen X; Gong Y; Wang X
Eur J Med Chem; 2020 Aug; 200():112359. PubMed ID: 32531682
[TBL] [Abstract][Full Text] [Related]
8. Targeted cancer therapy; nanotechnology approaches for overcoming drug resistance.
Gao Y; Shen JK; Milane L; Hornicek FJ; Amiji MM; Duan Z
Curr Med Chem; 2015; 22(11):1335-47. PubMed ID: 25666804
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.
Yang M; Liu H; Zhang Y; Wang X; Xu Z
Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464
[TBL] [Abstract][Full Text] [Related]
10. Perspectives in the development of hybrid bifunctional antitumour agents.
Musso L; Dallavalle S; Zunino F
Biochem Pharmacol; 2015 Aug; 96(4):297-305. PubMed ID: 26074269
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategies to overcome taxane resistance in cancer.
Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
[TBL] [Abstract][Full Text] [Related]
12. Designing multi-targeted agents: An emerging anticancer drug discovery paradigm.
Fu RG; Sun Y; Sheng WB; Liao DF
Eur J Med Chem; 2017 Aug; 136():195-211. PubMed ID: 28494256
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents.
Alam MM; Hassan AHE; Kwon YH; Lee HJ; Kim NY; Min KH; Lee SY; Kim DH; Lee YS
Arch Pharm Res; 2018 Jan; 41(1):35-45. PubMed ID: 29094267
[TBL] [Abstract][Full Text] [Related]
14. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
15. Chemical strategies to overcome resistance against targeted anticancer therapeutics.
Pisa R; Kapoor TM
Nat Chem Biol; 2020 Aug; 16(8):817-825. PubMed ID: 32694636
[TBL] [Abstract][Full Text] [Related]
16. Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers.
Zhou G; Latchoumanin O; Hebbard L; Duan W; Liddle C; George J; Qiao L
Adv Drug Deliv Rev; 2018 Sep; 134():107-121. PubMed ID: 29627370
[TBL] [Abstract][Full Text] [Related]
17. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
18. Coumarins as Potential Anti-drug Resistant Cancer Agents: A Mini Review.
Wang G; Sun S; Wu B; Liu J
Curr Top Med Chem; 2021; 21(19):1725-1736. PubMed ID: 33185162
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance.
Zha GF; Qin HL; Youssif BGM; Amjad MW; Raja MAG; Abdelazeem AH; Bukhari SNA
Eur J Med Chem; 2017 Jul; 135():34-48. PubMed ID: 28431353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
